Bridge City Capital LLC Trims Stake in Catalyst Pharmaceuticals, Inc. $CPRX

Bridge City Capital LLC lowered its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 14.1% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 156,683 shares of the biopharmaceutical company’s stock after selling 25,613 shares during the quarter. Bridge City Capital LLC owned approximately 0.13% of Catalyst Pharmaceuticals worth $3,657,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of CPRX. Public Sector Pension Investment Board raised its holdings in Catalyst Pharmaceuticals by 10.8% in the 3rd quarter. Public Sector Pension Investment Board now owns 516,745 shares of the biopharmaceutical company’s stock valued at $10,180,000 after acquiring an additional 50,343 shares during the last quarter. American Century Companies Inc. raised its holdings in Catalyst Pharmaceuticals by 43.8% in the 3rd quarter. American Century Companies Inc. now owns 2,528,186 shares of the biopharmaceutical company’s stock valued at $49,805,000 after acquiring an additional 770,198 shares during the last quarter. Rafferty Asset Management LLC raised its holdings in Catalyst Pharmaceuticals by 64.1% in the 3rd quarter. Rafferty Asset Management LLC now owns 157,044 shares of the biopharmaceutical company’s stock valued at $3,094,000 after acquiring an additional 61,328 shares during the last quarter. Royce & Associates LP raised its holdings in Catalyst Pharmaceuticals by 28.6% in the 3rd quarter. Royce & Associates LP now owns 2,034,965 shares of the biopharmaceutical company’s stock valued at $40,089,000 after acquiring an additional 452,103 shares during the last quarter. Finally, Fundsmith LLP raised its holdings in Catalyst Pharmaceuticals by 24.2% in the 3rd quarter. Fundsmith LLP now owns 3,363,807 shares of the biopharmaceutical company’s stock valued at $66,267,000 after acquiring an additional 654,721 shares during the last quarter. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Trading Down 0.0%

Shares of Catalyst Pharmaceuticals stock opened at $31.36 on Friday. The company has a fifty day moving average price of $29.16 and a 200 day moving average price of $25.63. Catalyst Pharmaceuticals, Inc. has a twelve month low of $19.05 and a twelve month high of $32.56. The stock has a market cap of $3.84 billion, a price-to-earnings ratio of 18.02, a price-to-earnings-growth ratio of 0.95 and a beta of 0.74.

Analyst Ratings Changes

Several research analysts have weighed in on CPRX shares. Robert W. Baird downgraded Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 7th. Weiss Ratings upgraded Catalyst Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, June 3rd. Wall Street Zen downgraded Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. HC Wainwright downgraded Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the company from $35.00 to $31.50 in a report on Thursday, May 28th. Finally, Truist Financial upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, March 25th. Two investment analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $32.00.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).